The polynuclear platinum BBR3610 induces G2/M arrest and autophagy early and apoptosis late in glioma cells

Neuro-Oncology

Volumn 12, Issue 12, 2010, Pages 1269-1277

  Shingu, Takashi ^a   Chumbalkar, Vaibhav C ^a   Gwak, Ho Shin ^a   Fujiwara, Keishi ^a   Kondo, Seiji ^a   Farrell, Nicholas P ^b   Bogler, Oliver ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Apoptosis; Autophagy; Cell cycle; Glioma; Platinum compounds

Indexed keywords

AUTOPHAGY PROTEIN 5; BBR 3610; BECLIN 1; CISPLATIN; PLATINUM DERIVATIVE; RAPAMYCIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL CULTURE; CELL AGING; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROTECTION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; RNA INTERFERENCE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; CISPLATIN; DRUG THERAPY, COMBINATION; G2 PHASE; GLIOMA; HUMANS; MEMBRANE PROTEINS; MICE; MICE, NUDE; MICROTUBULE-ASSOCIATED PROTEINS; ORGANOPLATINUM COMPOUNDS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78650126755     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noq095     Document Type: Article

References (26)

1. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermalgrowth factor receptor underlying responsiveness of non-small-celllung cancer to gefitinib. N Engl J Med. 2004;350:2129-2139.
2. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlationwith clinical response to gefitinib therapy. Science.2004;304:1497- 1500.
3. Billecke C, Finniss S, Tahash L, et al. Polynuclear platinum anticancerdrugs are more potent than cisplatin and induce cell cycle arrest inglioma. Neuro Oncol. 2006;8:215-226.
4. Farrell N. Polynuclear platinum drugs. Met Ions Biol Syst. 2004;42:251-296.
5. Perego P, Gatti L, Caserini C, et al. The cellular basis of the efficacy ofthe trinuclear platinum complex BBR 3464 against cisplatin-resistantcells. J Inorg Biochem. 1999;77:59-64.
6. Servidei T, Ferlini C, Riccardi A, et al. The novel trinuclear platinumcomplex BBR3464 induces a cellular response different from cisplatin.Eur J Cancer. 2001;37:930-938.
7. Pratesi G, Perego P, Polizzi D, et al. A novel charged trinuclear platinumcomplex effective against cisplatin-resistant tumours: hypersensitivity ofp53-mutant human tumour xenografts. Br J Cancer.1999;80:1912-1919.
8. Manzotti C, Pratesi G, Menta E, et al. BBR 3464: a novel triplatinumcomplex, exhibiting a preclinical profile of antitumor efficacy differentfrom cisplatin. Clin Cancer Res. 2000;6:2626-2634.
9. Farrell N. Polynuclear charged platinum compounds as a new class ofanticancer agents. Toward a new paradigm. In: Kelland, LR, Farrell,N, eds. Platinum-Based Drugs in Cancer Therapy. Totowa, NJ:Humana Press, 2000:321-338.
10. McGregor TD, Hegmans A, Kasparkova J, et al. A comparison of DNAbinding profiles of dinuclear platinum compounds with polyaminelinkers and the trinuclear platinum phase II clinical agent BBR3464.J Biol Inorg Chem. 2002;7:397-404.
11. Roberts JD, Peroutka J, Beggiolin G, et al. Comparison ofcytotoxicity and cellular accumulation of polynuclear platinum complexesin L1210 murine leukemia cell lines. J Inorg Biochem.1999;77:47-50.
12. Kondo Y, Kanzawa T, Sawaya R, et al. The role of autophagy in cancerdevelopment and response to therapy. Nat Rev Cancer.2005;5:726-734.
13. Fox JG. The Mouse in Biomedical Research. 2nd ed. Amsterdam;Boston: Elsevier, AP; 2007.
14. Diehl KH, Hull R, Morton D, et al. A good practice guide to the administrationof substances and removal of blood, including routes andvolumes. J Appl Toxicol. 2001;21:15-23.
15. Kanzawa T, Germano IM, Komata T, et al. Role of autophagy intemozolomide-induced cytotoxicity for malignant glioma cells. CellDeath Differ. 2004;11:448-457. (Pubitemid 38489422)
16. Kabeya Y, Mizushima N, Ueno T, et al. LC3, a mammalian homologueof yeast Apg8p, is localized in autophagosome membranes after processing.EMBO J. 2000;19:5720-5728.
17. Mizushima N. Methods for monitoring autophagy. Int J Biochem CellBiol. 2004;36:2491-2502.
18. Lal S, Lacroix M, Tofilon P, et al. An implantable guide-screw system forbrain tumor studies in small animals. J Neurosurg. 2000;92:326-333.
19. Boya P, Gonzalez-Polo RA, Casares N, et al. Inhibition of macroautophagytriggers apoptosis. Mol Cell Biol. 2005;25:1025-1040.
20. Maiuri MC, Zalckvar E, Kimchi A, et al. Self-eating and self-killing:crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol.2007;8:741-752.
21. Ishii N, Maier D, Merlo A, et al. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma celllines. Brain Pathol. 1999;9:469-479.
22. Kondo Y, Kondo S. Autophagy and cancer therapy. Autophagy.2006;2:85-90.
23. Fujiwara K, Daido S, Yamamoto A, et al. Pivotal role of the cyclindependentkinase inhibitor p21WAF1/CIP1 in apoptosis and autophagy.J Biol Chem. 2008;283:388-397.
24. Thorburn A. Apoptosis and autophagy: regulatory connections betweentwo supposedly different processes. Apoptosis. 2008;13:1-9.
25. Billecke C, Finniss S, Tahash L, et al. Polynuclear platinum anticancerdrugs are more potent than cisplatin and induce cell cycle arrest inglioma. Neuro-Oncology. 2006;8:215-226.
26. Zerzankova L, Suchankova T, Vrana O, et al. Conformation and recognitionofDNAmodified by a newantitumor dinuclear Pt(II) complex resistantto decomposition by sulfur nucleophiles. Biochem Pharmacol.2010;79:112-121.